Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 39Pancreatic Neoplasms 27Rectal Neoplasms 21Stomach Neoplasms 20Colonic Neoplasms 16Esophageal Neoplasms 11Neoplasm Metastasis 7Lymphoma, Large B-Cell, Diffuse 7Gastrointestinal Neoplasms 7Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Liver Neoplasms 4Cholangiocarcinoma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Prolymphocytic 2Glioblastoma 2Gastrointestinal Diseases 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

Capecitabine 6Bevacizumab 5trifluridine tipiracil drug combination 3Cetuximab 3Oxaliplatin 2sintilimab 1monoclonal antibody YYB-101 1aflibercept 1Vemurafenib 1Nivolumab 1LY-2157299 1Irinotecan 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Cancer Metastatic × Oxaliplatin × Clear all
NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Sun Yat-sen University

Phase 1/2 Active not recruiting
36 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT01955629 2016-04-18

AMOR

Sanofi

Phase 1/2 Terminated
4 enrolled 7 charts
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡